Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

    ... gene expression profile may predict response to lenalidomide in patients who lack the deletion of 5q31.1. Tools such as ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Myelodysplastic syndromes.

    ... diagnosis is 72 and the median survival is 2.5 years. Lenalidomide , azacitidine , and decitabine are all ...

    Research Article last updated 10/11/2011 - 5:58pm.

  3. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

    ... and del(5q) (P=0.10) cases with controls. Median lenalidomide response duration increased proportionate to C-allele dosage ...

    Research Article last updated 04/08/2015 - 11:21am.

  4. Treatment of myelodysplastic syndromes in elderly patients.

    ... is essential. Likewise, immunomodulatory drugs, such as lenalidomide , can reduce transfusion requirements and reverse cytologic ...

    Research Article last updated 02/10/2012 - 9:43am.

  5. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 02/04/2014 - 1:37pm.

  6. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 07/31/2012 - 2:02pm.

  7. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

    ... The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Azacitidine in the management of patients with myelodysplastic syndromes.

    ... has been combined with other novel agents such as lenalidomide , histone deacetylase inhibitors and growth factors in the hope ...

    Research Article last updated 05/14/2013 - 2:48pm.

  10. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... report. Abstract # 6522 The FDA approved lenalidomide in 2005 for treatment of lower risk MDS patients (low or ... that a majority of such patients who were treated with lenalidomide achieved sustained independence from RBC transfusions.  Moreover, ...

    Research Review last updated 05/02/2016 - 9:32am.